• Moderna secured FDA clearance for 2026-2027 versions of Spikevax, mNEXSPIKE targeting the JN.1-lineage XFG subvariant.
• Spikevax covers high-risk patients ages 6 months-64 years, all adults 65+; mNEXSPIKE covers high-risk ages 12-64, all 65+.
• Updated shots are expected to reach the US market in the coming days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.